Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Among authors: yu b. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Kahn RS, Silverman BL, DiPetrillo L, Graham C, Jiang Y, Yin J, Simmons A, Bhupathi V, Yu B, Yagoda S, Hopkinson C, McDonnell D. Kahn RS, et al. Among authors: yu b. Schizophr Res. 2021 Jun;232:45-53. doi: 10.1016/j.schres.2021.04.009. Epub 2021 May 17. Schizophr Res. 2021. PMID: 34015555 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 34127108
Identification of narciclasine as a novel NRF2 inhibitor.
Ngo HH, Yu BY, Lee JE, Kim H, Keum YS. Ngo HH, et al. Among authors: yu by. Free Radic Res. 2025 Jan 9:1-14. doi: 10.1080/10715762.2025.2451679. Online ahead of print. Free Radic Res. 2025. PMID: 39783823
12,460 results
You have reached the last available page of results. Please see the User Guide for more information.